Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway
Authors
Keywords
Rosiglitazone metformin adduct, Hepatocellular carcinoma, Proliferation, Metformin, AMPK/p21 pathway
Journal
Cancer Cell International
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-11
DOI
10.1186/s12935-019-0732-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolving Trends in the Epidemiology, Risk Factors, and Prevention of Type 2 Diabetes: A Review
- (2018) Alanna Weisman et al. CANADIAN JOURNAL OF CARDIOLOGY
- Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure
- (2018) Yvonne May Fen Chia et al. HEART FAILURE REVIEWS
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
- (2016) Nisa M. Maruthur et al. ANNALS OF INTERNAL MEDICINE
- Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes
- (2015) T. Dujic et al. DIABETIC MEDICINE
- Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis
- (2015) Liang Chen et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma
- (2013) L. Zheng et al. CLINICAL CANCER RESEARCH
- Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway
- (2013) GAO YI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Metformin use and improved response to therapy in esophageal adenocarcinoma
- (2012) Heath D. Skinner et al. ACTA ONCOLOGICA
- The Evaluation of Risk Factors Associated with Adverse Drug Reactions by Metformin in Type 2 Diabetes Mellitus
- (2012) Shinji Okayasu et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Diagnosis and Classification of Diabetes Mellitus
- (2012) DIABETES CARE
- Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones
- (2012) Domenico Motola et al. DRUG SAFETY
- Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
- (2012) Hsiao-Ping Chen et al. GUT
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis
- (2012) Hui Zhang et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients
- (2011) X.- X. He et al. ANNALS OF ONCOLOGY
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
- (2011) Meei-Shyuan Lee et al. BMC CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oral anti-diabetic drugs for the prevention of Type 2 diabetes
- (2011) O. J. Phung et al. DIABETIC MEDICINE
- The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
- (2011) Maria M. Mihaylova et al. NATURE CELL BIOLOGY
- Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
- (2010) M. Bodmer et al. DIABETES CARE
- Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naïve Patients with Type 2 Diabetes
- (2010) N. P. E. Kadoglou et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
- (2010) Bernard Zinman et al. LANCET
- Rosiglitazone, PPARγ, and Type 2 Diabetes
- (2010) Barbara B. Kahn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization
- (2009) D. D. Sears et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now